Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR LQDA
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers AVIR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.